Abstract
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type colorectal tumors. Information on the KRAS status of the patients tumor is thus key for clinical practice; however, there is little guidance or definition on which KRAS mutations to assess and how to assess them. To ensure the consistency and the quality of KRAS test results in Europe, an interlaboratory control network needs to be set up. This pilot study aimed to identify the variables that need to be assessed in a quality control scheme and to provide a first assessment in a selected set of laboratories. Fourteen different tumor cases were circulated between 13 laboratories by a central laboratory acting as the referent for the mutation status determination. This study illustrated that of 13 experienced laboratories that perform KRAS testing only ten correctly identified the KRAS in all 14 cases that were circulated. There was no harmonization in DNA isolation and KRAS mutation detection method between the laboratories. These results indicate that future standardization is needed in KRAS mutation detection methodology. An expansion of the European Society of Pathology KRAS program could identify areas of difficulty in KRAS testing and provide the basis for harmonization.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for a European quality assurance program. Virchows Arch 453:417–431
Van Krieken H, Tol J (2009) Setting future standards for KRAS testing in colorectal cancer. Pharmacogenomics 10(1):1–3
Monzon FA, Ogino S, Hammond ME et al (2009) The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133(10):1600–1606
Dequeker E, Cassiman JJ (2000) Genetic testing and quality control in diagnostic laboratories. Nat Genet 25(3):259–260
Dequeker E, Ramsden S, Grody WW et al (2001) Quality control in molecular genetic testing. Nat Rev Genet 2(9):717–723
Seneca S, Morris MA, Patton S et al (2008) Experience and outcome of 3 years of a European EQA scheme for genetic testing of the spinocerebellar ataxias. Eur J Hum Genet 16:913–920
Touitou I, Rittore C, Philibert L et al (2009) An international external quality assessment for molecular diagnosis of hereditary recurrent fevers: a 3-year scheme demonstrates the need for improvement. Eur J Hum Genet 17(7):890–896
Acknowledgments
This work was performed in collaboration with the European Society of Pathology. We would like to thank the KRAS Quality Assurance workgroup of ESP (alphabetically by name): Edsjo Anders (Sweden), E Dequeker (Belgium), K de Stricker (Denmark), A Ensari, G Hoefler (Austria), A Jung (Germany), A Kotsinas (Greece), M Ligtenberg (The Netherlands), F Lopez-Rios (Spain), JC Machado (Portugal), M Marichal (Belgium), C Mazzanti (Italy), TP Hansen (Denmark), S Richman (United Kingdom), E Rouleau (France), S Tejpar (Belgium), and JHJM van Krieken (The Netherlands). The authors thank the participating laboratories in this pilot scheme; Prof. G Hofler and Prof. A Kotsina for providing tissue blocks for this scheme; Prof. G De Hertogh for evaluating the tissue blocks; Prof. dr P Vandenbergh for the molecular analysis; the technicians from the departments of pathology in Leuven and Nijmegen for the preparation of the slides and the validation of the samples; W De Kelver, B Biesmans, and K Cox for the assistance in the evaluation of the results; and E Bellon for the administrative support.
Conflict of interest
The authors have declared no conflicts of interest.
Funding
The work was supported by a grant of AMGEN.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dequeker, E., Ligtenberg, M.J.L., Vander Borght, S. et al. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. Virchows Arch 459, 155–160 (2011). https://doi.org/10.1007/s00428-011-1094-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-011-1094-x